Bayer and JD Health Sign Deep Cooperation Agreement to Build a Lifespan-Centric Women's Health Management Ecosystem

China Finance and Economics News, March 1st: Today, Bayer Pharmaceuticals Co., Ltd. ("Bayer") and JD Health International Inc. ("JD Health") officially signed an in-depth cooperation agreement in Beijing, marking a new phase in their collaboration in the field of women's health.

This collaboration will integrate Bayer's professional expertise in the healthcare field with JD Health's digital platform resources, focusing on building a health management ecosystem that covers the entire life cycle of women.

Since establishing a partnership in 2017, the two parties have achieved significant cooperation results in areas such as pharmaceutical e-commerce, smart medical services, precision health management, and public welfare projects. Based on seven years of cooperation, this deepened collaboration upgrade will focus on three core directions: In terms of medical services, leveraging Bayer's expertise in women’s health and JD Health’s internet platform, a full-chain solution will be developed covering contraception management, diagnosis and treatment of polycystic ovary syndrome, management of gynecological endocrine diseases, and menopause management. This initiative aims to enhance the coverage of internet-based medical services in the field of women’s health, breaking the limitations of time and region, and providing more women with convenient, timely, and professional medical services.

In terms of ecological construction, the two parties will jointly build a multi-party dialogue platform involving the government, medical institutions, experts, etc., to promote academic exchanges and policy advocacy on women's health. At the same time, they will also focus on strengthening science popularization education for women’s health, improve the level of internet-based medical diagnosis and treatment, and jointly create Bayer's women's health ecosystem.

At the innovation technology level, JD Health leverages its software and hardware advantages in areas such as online channels, logistics distribution, big data, health management, and internet pharmaceuticals and healthcare. At the same time, through medical big data analysis and AI-assisted diagnosis systems, it realizes fully digitalized services from online consultations to medicine delivery.

"As a leading enterprise in the global life sciences field, Bayer has always regarded improving women's health as an important mission. We are accelerating the construction of women's whole-life-cycle health management through collaborative innovation," said Yuan Junjie, Vice President of Bayer Group's Pharmaceuticals Division and General Manager of China Women's Health Business. This in-depth cooperation upgrade is not only a milestone in the partnership between the two parties but also a new paradigm for the integration and development of pharmaceutical innovation and digital healthcare. Both parties will mutually promote each other in the continuously deepening cooperation, explore the boundaries of digital and intelligent healthcare, and jointly advance the high-quality development of women’s health in China.

The Vice President of JD Health and General Manager of the pharmaceuticals business department said that this in-depth cooperation upgrade will achieve a multiplier effect between JD Health's digital ecosystem and Bayer's professional medical resources, promoting the introduction of more innovative products and services. With user health as the starting point, digital intelligence technology as the engine, an open ecosystem as the support, and sustainable development as the responsibility, JD Health will not only optimize the efficiency and experience of women’s healthcare services but also focus on driving industry transformation together with its partners.